Therefore, therapies targeting the CXCLs/CXCR2 axis and/or IL-1β signaling may increase the RT-mediated innate response and immune-modulation through shaping tumor-infiltrating neutrophil activity in the TME. The gene discussed is IL1B; the disease is neoplasm.